Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 16, 2016 16:30 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Reports First Quarter 2016 Financial and Business Update

FLEMINGTON, N.J., May 16, 2016 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other...
April 19, 2016 08:00 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics to Focus Clinical Developmental Activities on Advanced Prostate Cancer in First-of-its-Kind Phase II Study of Onapristone in Combination with ZYTIGA®

FLEMINGTON, N.J., April 19, 2016 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company dedicated to the development of therapeutics for cancer and...
March 30, 2016 16:16 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update

FLEMINGTON, N.J., March 30, 2016 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other...
March 21, 2016 07:30 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Advances Phase I/II Trial Evaluating Onapristone in Prostate Cancer to Phase II

- Phase II to include study of onapristone in combination with abiraterone - FLEMINGTON, N.J., March 21, 2016 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage...
January 13, 2016 07:30 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Completes $7.4 Million Common Stock Financing

FLEMINGTON, N.J., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...
November 16, 2015 16:00 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Reports Third Quarter 2015 Financial Results and Business Update

FLEMINGTON, N.J ., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...
October 29, 2015 07:00 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis

FLEMINGTON N.J., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and...
October 21, 2015 10:01 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains

FLEMINGTON, N.J., Oct. 21, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and...
September 25, 2015 06:00 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference

FLEMINGTON, N.J., Sept. 25, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...
September 24, 2015 07:00 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics' AR-13 Data Show Promise as Potential New Therapeutic Option for Cystic Fibrosis Patients With Serious Bacterial Infections

FLEMINGTON, N.J., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...